Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MLYCD | O95822 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70806 | 0.96 | HPGD (0.79) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL3905925 | 0.94 | HPGD (0.83) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL9133746 | 0.91 | ALDH1A1 (0.64) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL10721733 | 0.86 | HPGD (0.95) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL1263133 | 0.84 | HPGD (0.88) | HPGDALDH1A1MAPK1SMN1; SMN2LMNA | |
| SCHEMBL27479149 | 0.84 | HPGD (1.00) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL7132525 | 0.84 | HPGD (1.00) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL1975158 | 0.83 | HPGD (0.72) | HPGDALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL2614241 | 0.83 | HPGD (0.84) | HPGDALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL23140495 | 0.82 | SIGMAR1 (0.76) | HPGDALDH1A1MAPK1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883636-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2008-02-06 | — | — | EP | claimed |
| US-20060293298-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | claimed |
| WO-2006125665-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | claimed |
| CN-110759889-B | 2-aryl amido substituted thiophene imide ester compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2022-05-20 | — | — | CN | disclosed |
| CN-110759889-A | 2-aryl amido substituted thiophene imide ester compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2020-02-07 | — | — | CN | disclosed |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| CN-101679237-A | The method of preparation (R)-2-crassitude and (S)-2-crassitude and tartrate thereof | CEPHALON INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| EP-1883636-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| US-20060293298-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| WO-2006125665-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | HPGD 550/4885ALDH1A1 1386/4885MAPK1 3388/4885 |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | HRH3, HRH1, HRH4 | HPGD 617/4885ALDH1A1 1586/4885MAPK1 1859/4885 |
| US-20060293298-A1 | Compounds | NQO1, OPRM1, CAT | HPGD 784/4885ALDH1A1 95/4885MAPK1 3413/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | HPGD 550/4885ALDH1A1 1386/4885MAPK1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.